中山大學(xué)循證醫(yī)學(xué)3translationalmedicine_zsu_fs-資料下載頁
2025-03-22 01:13本頁面
【正文】 cal care to that individual39。s needs Imatinib for GIST ? GIST genesis – Key process： ckit mutationKIT TK activation – PDGFR mutation – 86% GIST kit mutation， prognosis factor ? Imatinib – Oral small molecule TKI – Inhibit TK activation抑制酪氨酸激酶活化 – Design for chronic myeloid leukemia (CML) Imatinib for GIST Imatinib for GIST ? Joensuu H， et al. 2022 Pretreatment One month of therapy Hamp。E (at diagnosis) Hamp。E Ki 67 CD117 Joensuu H et al. N Engl J Med. 2022。344:10521056. The First GIST Patient: Histology Imatinib for GIST Imatinib for GIST ? Joensuu H， et al. 2022 – Theory： Imatinib could target GIST – Easy Detected tumor marker： CD117 – Tissue from the patient ? Response confirmed by pathology ? Dynamic monitored by tumor marker – Ethics： ? IRB Imatinib 治療 GIST ? ： Joensuu H. first case ? ： phase II study(B2222) ? 2022 autumn： phase II study (S0033,EORTC) ? ： FDA Imatinib for GIST ? 5year survival – Kit mutation predict Imatinib response Imatinib for GIST Imatinib for GIST ? Imatinib resistance clinic→lab ? Overe Imatinib resistance lab → clinic ? Mechanism of Imatinib resistance clinic→lab Imatinib for GIST ? Surgery in advance GIST ? When to stop? ? Choi’s Imatinib for GIST Choi et al, J Clin Oncology, 2022。25:17531759 Imatinib for GIST ? Ckit activation normally associated with KIT mutations ? Ckit activation sometimes without KIT mutations ? Some ckit negative tumors have KIT mutations ? Some ckit negative GISTs have activating mutations in a different TK (tyrosine kinase), PDGFRa ? …… Summary ? Clinical expertise is important ? EBM: improve clinical practice and research ? Translational Medicineamp。Personalized Medicine: new trend ? Integration of EBM and Translational Medicine THINK BIG ! start small 謝 謝！
環(huán)評公示相關(guān)推薦
鄂ICP備17016276號-1